The Technical Analyst
Biotricity, Inc. [BTCY]
Exchange: PNK Industry: Medical Devices
Biotricity, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
8.14% $1.460
America/New_York / 22 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 13.52 mill |
| EPS: | -1.750 |
| P/E: | -0.830 |
| Earnings Date: | Jun 28, 2024 |
| SharesOutstanding: | 9.26 mill |
| Avg Daily Volume: | 0.0956 mill |
| RATING 2024-04-22 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.830 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.830 | industry: PE -6.92 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.282 - 1.638 ( +/- 12.19%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-03-12 | Rosa David A | Buy | 75 930 | Option (right to buy) |
| 2023-03-12 | Al-siddiq Waqaas | Buy | 1 000 000 | Option (right to purchase) |
| 2023-03-12 | Al-siddiq Waqaas | Buy | 350 000 | Option (right to purchase) |
| 2023-03-12 | Al-siddiq Waqaas | Buy | 350 000 | Option (right to purchase) |
| 2022-12-31 | Ayanoglou John | Buy | 218 785 | Warrants |
| INSIDER POWER |
|---|
| 100.00 |
| Last 57 transactions |
| Buy: 8 034 693 | Sell: 4 236 769 |
Forecast:
16:00 - $1.460
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.460
Forecast 2: 16:00 - $1.460
Forecast 3: 16:00 - $1.460
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.460 (8.14% ) |
| Volume | 0.102 mill |
| Avg. Vol. | 0.0956 mill |
| % of Avg. Vol | 106.61 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BTCY
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BTCY
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions primarily in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.
Last 10 Buy Signals
Latest Press Releases
2024-04-18 07:00:00 - Press Release
Biotricity Launches Major Cardiac Monitoring Pilot Program In A Hospital System Comprised Of 9 Hospitals And 10 Clinics
Redwood city, ca / accesswire / april 18, 2024 / biotricity inc. (nasdaq:btcy) a leading technology-as-a-service (taas) company at the forefront of medical diagnostics and consumer healthcare, announces a groundbreaking cardiac monitoring pilot program with a prestigious hospital group spanning 9 hospitals and 10 clinics. biotricity will work closely with healthcare professionals to optimize patient interaction protocols and streamline data collection processes.
2024-04-16 07:00:00 - Press Release
Biotricity Launches Cardiac Monitoring Pilot Program With Major Hospital Network
Redwood city, ca / accesswire / april 16, 2024 / biotricity inc. (nasdaq:btcy) ("biotricity" or the "company"), a leading technology-as-a-service (taas) company revolutionizing the medical diagnostic and consumer healthcare field, launched a pilot program with a major hospital network, encompassing over 50 hospitals across multiple states. the pilot program will demonstrate the value of biotricity's cardiac monitoring solutions, setting the stage for a potential large-scale commercial rollout across the network.
2024-04-02 07:15:00 - Press Release
Biotricity Announces A Strategic Partnership For Cardiac Screenings In Patients With Co-morbidities
Redwood city, ca / accesswire / april 2, 2024 / biotricity inc. (nasdaq:btcy) ("biotricity" or the "company"), a leading technology-as-a-service (taas) company revolutionizing the medical diagnostic and consumer healthcare field, continues its strategic expansion with the announcement of its latest partnership in neurology to conduct cardiac screenings in patients suffering from neurological issues. there are over 1,000 neurological disorders and over 100 million americans suffering from at least 1 neurological issue.
2024-03-28 10:00:00 - Press Release
Lobo Ev And Biotricity Interviews To Air On The Redchip Small Stocks, Big Money(tm) Show On Bloomberg Tv
Orlando, fl / accesswire / march 28, 2024 / redchip companies will air interviews with lobo ev technologies ltd. (nasdaq:lobo) and biotricity, inc. (nasdaq:btcy) on the redchip small stocks, big money™ show, a sponsored program on bloomberg tv, this saturday, march 30, at 7 p.m.
2024-03-28 08:15:00 - Press Release
Biotricity Accelerates Market Access By Partnering With Third Major Group Purchasing Organization, Expanding Market Reach To 90% Of U.s. Hospitals
Redwood city, ca / accesswire / march 28, 2024 / biotricity inc. (nasdaq:btcy) ("biotricity" or the "company"), a leading technology-as-a-service (taas) company revolutionizing the medical diagnostic and consumer healthcare field, continues its strategic expansion with the announcement of its latest partnership with yet another leading group purchasing organization (gpo). gpos streamline purchasing processes for medical providers and systems.
Latest News
2024-04-04 10:56:13 - Zacks Investment Research
Biotricity (BTCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Biotricity (BTCY), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
2024-03-14 09:51:09 - Zacks Investment Research
Here Is Why Bargain Hunters Would Love Fast-paced Mover Biotricity Inc. (BTCY)
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Biotricity Inc. (BTCY) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
2024-03-07 13:01:10 - Zacks Investment Research
Biotricity Inc. (BTCY) Upgraded to Buy: Here's What You Should Know
Biotricity Inc. (BTCY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2024-02-20 19:21:06 - Zacks Investment Research
Biotricity Inc. (BTCY) Reports Q3 Loss, Misses Revenue Estimates
Biotricity Inc. (BTCY) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.54 per share a year ago.
2024-02-19 08:00:00 - Accesswire
Biotricity to Host Third Quarter Fiscal Year 2024 Financial Results and Business Update Call on February 21st
REDWOOD CITY, CA / ACCESSWIRE / February 19, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, announced that it will host its Third Quarter Fiscal Year 2024 Financial Results and Business Update Call on Wednesday, February 21, 2024. Biotricity Founder and CEO Dr. Waqaas Al-Siddiq and CFO John Ayanoglou will deliver remarks followed by a Q&A section to address questions from investors.
2024-02-14 08:00:00 - Accesswire
Biotricity Advances Towards Breakeven Milestone - Set to Announce Record Margins and Operational Efficiency for Third Quarter of Fiscal Year 2024
Company continues its shift to subscription-based revenue, prioritizing margin improvement and operational efficiency enhancements, on the path to breakeven Management to announce Third Quarter Fiscal 2024 Results at market close on February 20, 2024 REDWOOD CITY, CA / ACCESSWIRE / February 14, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, provided selected preliminary financial results for its fiscal third quarter 2024 results, ended December 31, 2023, that include record gross margins and record operational efficiency. For the Third Quarter of Fiscal Year 2024, the Company expects to announce: Record gross margins of 73% compared to the prior year quarter of 57% Improved operational efficiency, reflected in a reduction in operating expenses of over 30% The results for our third quarter will demonstrate year-over-year improvements in all key operating metrics- specifically in operational costs and gross margins.
2023-11-14 21:25:06 - Seeking Alpha
Biotricity, Inc. (BTCY) Q2 2024 Earnings Call Transcript
Biotricity, Inc. (NASDAQ:BTCY ) Q2 2024 Earnings Conference Call November 14, 2023 6:00 PM ET Company Participants Debra Chen - IR Waqaas Al-Siddiq - Founder and CEO John Ayanoglou - CFO Conference Call Participants Michael Davin - H.C. Wainwright Operator Good afternoon, and welcome to Biotricity's Second Quarter Fiscal 2024 Financial Results and Business Update Conference Call.
2023-11-10 09:30:00 - Accesswire
Biotricity to Host Second Quarter Fiscal Year 2024 Financial Results and Business Update Call on November 14th
Biotricity improves margins while lowering selling expenses and operating losses REDWOOD CITY, CA / ACCESSWIRE / November 10, 2023 / Biotricity Inc. (Nasdaq:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, announced that it will host its Second Quarter Fiscal Year 2024 Financial Results and Business Update Call on Tuesday, November 14, 2023. Biotricity Founder and CEO Dr. Waqaas Al-Siddiq and CFO John Ayanoglou will deliver remarks followed by a Q&A section to address questions from investors.
2023-08-15 21:13:04 - Seeking Alpha
Biotricity (BTCY) Q1 2024 Earnings Call Transcript
Biotricity (NASDAQ:BTCY ) Q1 2024 Earnings Conference Call August 15, 2023 4:30 PM ET Company Participants Debra Chen – Investor Relations Waqaas Al-Siddiq – Founder and Chief Executive Officer John Ayanoglou – Chief Financial Officer Conference Call Participants Kevin Dede – H.C. Wainwright Operator Good afternoon, and welcome to Biotricity's First Quarter Fiscal 2024 Financial Results and Business Update Conference Call.
2023-08-14 08:15:00 - Accesswire
Biotricity to Host First Quarter Fiscal Year 2024 Financial Results and Business Update Call on August 15th
REDWOOD CITY, CA / ACCESSWIRE / August 14, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, announced that it will host its First Quarter Fiscal Year 2024 Financial Results and Business Update Call on Tuesday, August 15, 2023. Biotricity Founder and CEO Dr. Waqaas Al-Siddiq and CFO John Ayanoglou will deliver remarks followed by a Q&A section to address questions from investors.